Rocio García‐Carbonero

Universidad Complutense de Madrid ES

0000-0002-3342-397X

588

Publications

19,477

Citations

H-Index

217

i10-Index

6.75

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

585 total

Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.

T. Macarulla, M. Cecchini, R. García-Carbonero, T. Golan, Ruth Perets - Journal of Clinical Oncology, 2024

Cited by 0 Semantic Scholar

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

Thierry Andre, E. Élez, Eric Van Cutsem, Lars Henrik Jensen, J. Bennouna - Journal of Clinical Oncology, 2024

Cited by 53 Semantic Scholar

Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.

S. Stintzing, J. Tabernero, T. Satoh, A. Dasari, S. Lonardi - Journal of Clinical Oncology, 2024

Cited by 2 Semantic Scholar

Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence OA

Andrés Cervantes, J. Tabernero, R. García-Carbonero, Javier Sastre, Jaime Feliú - Future Oncology, 2024

Cited by 1 Semantic Scholar

Abstract 6408: Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2

S. Lonardi, A. Dasari, R. García-Carbonero, T. Yoshino, P. García-Alfonso - Cancer Research, 2024

Cited by 0 Semantic Scholar

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours OA

A. Rinke, V. Ambrosini, C. Dromain, R. García-Carbonero, A. Haji - Journal of neuroendocrinology, 2023

Cited by 125 Semantic Scholar

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer OA

P. Romesser, J. Capdevila, R. García-Carbonero, T. Philip, C. Fernández-Martos - Clinical Cancer Research, 2023

Cited by 22 Semantic Scholar

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward? OA

R. García-Carbonero, Beatriz Antón-Pascual, A. Modrego, M. Riesco-Martinez, A. Lens-Pardo - Endocrine reviews, 2023

Cited by 36 Semantic Scholar

Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)

E. Cohen, J. Fayette, A. Daste, C. Even, C. Tourneau - Cancer Research, 2023

Cited by 5 Semantic Scholar

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study PDF

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen et al. - The Lancet Oncology, 2022

Cited by 845 OpenAlex

Research Topics

Colorectal Cancer Treatments and Studies (241) Neuroendocrine Tumor Research Advances (187) Lung Cancer Research Studies (139) Pancreatic and Hepatic Oncology Research (108) Gastric Cancer Management and Outcomes (82)

Affiliations

Université Claude Bernard Lyon 1

FR 2016 - 2016

Universidad Complutense de Madrid

ES 2025 - 1997

Hebron University

PS 2015 - 2015

Universitat Autònoma de Barcelona

ES 2013 - 2013

National Institutes of Health

US 2005 - 2005

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

Rocio García‐Carbonero

Publication & Citation Trends

Publications

Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.

Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence OA

Abstract 6408: Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours OA

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer OA

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward? OA

Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study PDF

Research Topics

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back